ArticleEcancermedicalscience2025
Real-world outcomes of women with metastatic breast cancer in visceral crisis treated with chemotherapy: a 15-year cohort from Brazil.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Management of Hepatic Visceral Crisis Using Chemoimmunotherapy in PD-L1-High Metastatic Triple-Negative Breast Cancer: A Case Report.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Visceral crisis (VC) in metastatic breast cancer (MBC) is defined as a severe organ dysfunction related to metastatic disease. The cornerstone of treatment for VC relies on polychemotherapy, particularly in low- and middle-income countries, where it often represents the only available therapeutic option. This study aims to assess survival outcomes of palliative chemotherapy (CT) for VC in a real-world scenario. Methods: Data were retrospectively collected from patients with MBC diagnosed with VC between 2008 and 2022 in a large cancer center in Brazil. Survival analyses were performed using the Kaplan-Meier method. Prognostic factors were evaluated through univariate and multivariable analyses using the Cox regression model. Results: A total of 146 patients with VC were included. The predominant type of VC was pulmonary (36.3%), hepatic (32.2%) and bone marrow infiltration (19.2%). VC management was based on combination CT (51.4%), while 27.4% were treated with monochemotherapy and 20.6% received best supportive care (BSC). The median overall survival (mOS) for the entire population was 2.17 months. Treatment for VC in the first-line setting was associated with a mOS of 5 months. In the multivariate analysis, hepatic VC and the absence of active oncological therapy (BSC) were significantly associated with mortality. Conclusion: Patients with MBC in VC have a poor prognosis even when treated with polychemotherapy. Proper prognostication is crucial for identifying patients who may benefit from active systemic therapy while carefully avoiding potentially futile strategies. Prospective trials including patients with VC criteria are needed to evaluate the efficacy and safety of CT and other emerging therapies in this scenario.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.